Buy box is not available to display at this moment. Sorry for the inconvenience
To purchase this book, please visit this page later or call our 24/7 customer service

  • Summary

  • Find out what you need to know for your personal lung cancer journey through stories and interviews with patients, lung cancer specialists, and key participants in the quest for a cure.
    Copyright 2019-2021 Lung Cancer Foundation of America All rights reserved.
    Show More Show Less
Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • Comprender los biomarcadores del cáncer de pulmón

    Comprender los biomarcadores del cáncer de pulmón
    Jul 7 2022

    Un diagnóstico de cáncer de pulmón llegó de repente para Emma Pompeo. Pero afortunadamente, ella tenía dos cosas a su favor: apoyo de su familia cuando aprendió de su diagnóstico y encontró a un doctor en un centro de cáncer comprensivo que podía contestar sus preguntas en español para que ella y su familia pudieran entender toda la nueva información. Su doctor le explicó bien sobre los biomarcadores de cáncer de pulmón, organizó los exámenes requeridos, y dio buenas recomendaciones de otros doctores quienes ayudaron a formar su equipo de salud. Estos diálogos eran increíblemente importantes mientras ella aprendía el nuevo vocabulario que es parte del diagnóstico de cáncer de pulmón y del tratamiento apropiado.

    INVITADOS

    Dr. Christian Rolfo es un Oncólogo Torácico y experto en oncología molecular, biopsias líquidas y desarrollo de nuevos fármacos en el ámbito de cáncer de pulmón y mesotelioma en el centro de Oncología Torácica de Mount Sinai.

    Emma Pompeo está viviendo con EGFR cáncer de pulmón. Ella dedica tiempo a ser una luchadora para pacientes, apoyando a otros en su experiencia con cáncer de pulmón.

    Notas del Programa | Transcripción

     
    Show More Show Less
    Not Yet Known
  • Investment in grants change the future for lung cancer patients

    Investment in grants change the future for lung cancer patients
    Dec 17 2021
    Lung cancer is a disease that affects people: family, friends, co-workers, neighbors. It's a disease that comes with in some stark figures about survival and research funding. But the numbers don't lie, and they also show the amazing strides being made against the disease: increasing survival rates, incredible strides in treatment options, and ever-growing ranks of researchers dedicating their professional careers to improving the odds for people living with lung cancer. Join us for this episode of Hope With Answers: Living With Lung Cancer, where we talk about hope, by the numbers. Guests: Kim Norris, Lung Cancer Foundation of America co-founder and president Dr. Jessica Donington, professor of surgery at the University of Chicago Pritzker School of Medicine Dr. Triparna Sen, an assistant attending at Memorial Sloan Kettering Cancer Center Kellie Smith, PhD, assistant professor of oncology at Johns Hopkins Medicine   Show Notes | Transcript BY THE NUMBERS: 20  The quickening pace of research the last 20 years Twenty years ago, the lung cancer treatments available were surgery, chemotherapy, and radiation. Then came the discovery of treatable lung cancer biomarkers. The discovery that each lung cancer tumor is unique opened up a whole new world of discovery. After that, immunotherapy opened up even more ways to treat different types of lung cancer. And for many people, living with lung cancer it has become more like managing a chronic disease rather than the usually fatal diagnosis it was just a handful of years ago. “... the entire landscape has changed for people diagnosed with lung cancer. I even wonder if my husband, who died 20 years ago, would still be alive if he had been able to take advantage of all the research that’s been happening in just the past five or ten years. We now know people living 8, 13, 15, and 19 years after diagnosis. And then we realized that these numbers are really powerful-- they’re not just black and white numbers, they’re people.“ - Kim Norris BY THE NUMBERS: Double Duty LCFA Young Investigator Research Grants do double duty in the field of lung cancer research. Funding from foundations like the Lung Cancer Foundation of America is essential in building a pool of investigators. It takes a long time and a lot of money to go from a great idea and a bright star with a great mind to an NIH-funded investigator. But as Dr. Triparna Sen points out, these grants also help to train young investigators. “Like with this funding, we get postdocs and trainees and technicians into the lab. So we are essentially training the next generation of cancer investigators who will go on to become in independent investigators themselves. So you're not only just providing resource to advanced research, but you're also providing resource to train the next generation of cancer investigators. And I think that has a much more long term impact the next clinical trial. So I think overall, uh, the funding that I got from LCFA has been absolutely critical in developing me as a researcher. So thank you so much.” BY THE NUMBERS: 17 LCFA has invested in 17 grants so far, and 10 of them have gone to women. Women in science face many challenges. When Dr. Donington got into lung cancer 15 years ago, it was a very male-dominated field in terms of the doctors who treated it and the researchers who performed the research. And I always believe that a group of physicians and researchers that matches their patients provides the best care. The Power Of The Patient Advocate Voice Women advocates are making a difference in lung cancer research as well. As Dr. Donington discusses, “Lung cancer for a long time has had a stigma issue as being seen as a male disease, with people who have smoked for 100 years. And it's just not, it's not that disease. And I think that our advocates which are very heavily female like a lot of cancer advocates are, have really done so much to change the face of lung cancer…. I think they do more to change lung cancer than even us as investigators.” Dr. Sen thinks that what the patient advocates do is they help bring system-wide issues to light that are required for clinical trial design for what is important for the actual patients who is the ultimate goal role for our researchers. And her goal is to work with patient advocates to make her scientific studies more relevant to the field, more timely, because she now understand by speaking to them the urgency of the situation, and so make it more timely. “And I think patient advocates play a very important role to help researchers learn like myself move discoveries towards clinical use, but do that in a more sort of not only timely fashion, but also help us design studies that are more relevant to clinical use.” - Dr. Triparna Sen In addition, patient advocates play an important role in bringing these disparities to light. Then these issues can be addressed by researchers and by clinicians and move them to ...
    Show More Show Less
    Not Yet Known
  • Understanding Gut Microbiome in Lung Cancer Treatment

    Understanding Gut Microbiome in Lung Cancer Treatment
    Oct 7 2021

    What if your lung cancer doctor could get a huge amount of information about your health, how you might respond to different treatments, and possibly even be able to tell you the best diet for your specific needs, all based on a simple test that involves no needles, no surgery, no special preparation, just a small sample… of your stool. That’s the potential of studying the gut microbiome. Find out why some of LCFA’s Young Investigators are so excited about including the gut microbiome in the fight against lung cancer.

    Guests

    Dr. Jarushka Naidoo Dr. Daniel Spakowicz Dr. Zoltan Loinai

    Dr. David Carbone, The Ohio State University

    Show Notes | Transcription

    Getting over the ick factor: Talking about poop

    The immune effect of the microbiome on lung cancer may be due to specific compositions of both lung and gut microbiomes. Three of LCFA’s Young Investigator grant recipients are continuing this study of gut microbiome and lung cancer, Dr. Jarushka Naidoo, Dr. Daniel Spakowicz, and Dr. Zoltan Lohinai.

    The Future is Gut Microbiomes, Icky As it May Be

    Discovering whether a patient’s gut health plays a role in determining the benefits – or, conversely, the harm – of immunotherapy treatment. Until now, there has been scant research connecting gut health with both cancer diagnoses and treatment protocols.

    The LCFA Young Investigator Grants are designed to help researchers look at lung cancer in new and creative ways, always with an eye toward finding better treatments that help people live longer and healthier lives.Familiarizing the practicing clinician with the experimental methods used to generate the information that will likely impact the field of lung cancer, helping to understand gut microbiome in lung cancer treatment.

    As Dr. Daniel Spakowicz says, “in general, collecting somebody’s poop before they start a treatment is not a commonly done practice right now, and it tends to be sort of icky to some people. And that’s the essence of what we want to change.”
    Show More Show Less
    Not Yet Known

What listeners say about Hope With Answers: Living With Lung Cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews
No Reviews are Available